Loading stock data…
GRAIL, Inc. (GRAL)
$68.39+2.47 (+3.75%)
Market ClosedLast close Jun 29
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRAIL, Inc. in the Healthcare sector is trading at $68.39 with a market capitalization of $2.6B. Wall Street consensus targets $66.00 (8 analysts), implying a -3.5% move over the next 12 months. The stock is currently 42% below its 52-week high of $118.84, remaining 5.4% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.78M↓ | $43.60M↑ | $36.19M↑ | $35.54M↑ | $31.84M |
| Gross Profit | -$14.31M↓ | -$11.14M↑ | -$13.73M↑ | -$17.77M↑ | -$19.93M |
| Operating Income | -$135.76M↓ | -$124.41M↑ | -$125.29M↑ | -$130.85M↑ | -$153.61M |
| Net Income | -$93.19M↑ | -$99.18M↓ | -$88.98M↑ | -$113.98M↓ | -$106.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.81%
Volume
Today's trading volume
482,081
Recent News
A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors.
Despite a significant setback, Grail's Galleri test still has a pathway to widespread adoption.
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
HON will own a large stake in Quantinuum following the IPO.
A Look At GRAIL (GRAL) Valuation After A Sharp One Day Share Price Drop
GRAIL stock reaction and recent performance GRAIL (GRAL) shares recently moved after a single day decline of about 10%, drawing attention to how the stock’s sharp daily move compares with its gains over the past month and past 3 months. See our latest analysis for GRAIL. That 10.16% one day share price drop comes after a 19.13% 30 day share price return and a 22.06% 90 day share price return. Yet year to date the share price is still down 27.53%, even as the 1 year total shareholder return...
Grail Plummets On Mixed Results For Cancer-Screening Blood Test
Grail stock plummeted Monday on mixed results for its landmark study, comparing blood test Galleri with traditional cancer screening methods.
GRAIL (GRAL) Is Up 6.7% After Mixed Galleri Trial Data At ASCO 2026 - Has The Bull Case Changed?
At the 2026 ASCO Annual Meeting, GRAIL reported full results from the NHS-Galleri and PATHFINDER 2 studies, showing its Galleri blood test shifted cancer detection toward earlier stages and reduced Stage IV diagnoses by over 20% in later screening rounds, while maintaining strong performance and a favorable safety profile. An important nuance is that although NHS-Galleri highlighted earlier detection benefits, it did not meet its primary endpoint of reducing the combined incidence of Stage...